Perspective Therapeutics Beheer
Beheer criteriumcontroles 1/4
Perspective Therapeutics' CEO is Thijs Spoor, appointed in Feb 2023, has a tenure of 1.75 years. total yearly compensation is $1.46M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $250.92K. The average tenure of the management team and the board of directors is 1.7 years and 1.8 years respectively.
Belangrijke informatie
Thijs Spoor
Algemeen directeur
US$1.5m
Totale compensatie
Percentage CEO-salaris | 34.7% |
Dienstverband CEO | 1.8yrs |
Eigendom CEO | 0.03% |
Management gemiddelde ambtstermijn | 1.7yrs |
Gemiddelde ambtstermijn bestuur | 1.8yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$52m |
Mar 31 2024 | n/a | n/a | -US$50m |
Dec 31 2023 | US$1m | US$506k | -US$37m |
Compensatie versus markt: Thijs's total compensation ($USD1.46M) is below average for companies of similar size in the US market ($USD3.24M).
Compensatie versus inkomsten: Insufficient data to compare Thijs's compensation with company performance.
CEO
Thijs Spoor (52 yo)
1.8yrs
Tenure
US$1,458,996
Compensatie
Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 1.8yrs | US$1.46m | 0.031% $ 250.9k | |
CFO and Principal Financial & Accounting Officer | 5.9yrs | US$1.17m | 0.053% $ 434.9k | |
Chief Medical Officer | 1.8yrs | US$900.09k | 0.20% $ 1.7m | |
Executive Vice President of Operations | 1.3yrs | geen gegevens | geen gegevens | |
Chief Science Officer | no data | geen gegevens | 2.2% $ 17.9m | |
Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
Executive Vice President of Brachytherapy | 1.6yrs | geen gegevens | geen gegevens | |
Chief Business Strategy Officer | no data | geen gegevens | geen gegevens | |
Chief Innovation Officer | no data | geen gegevens | 2.2% $ 17.9m | |
Senior Vice President of Clinical Operations | no data | geen gegevens | geen gegevens | |
Senior Vice President of Clinical Development | less than a year | geen gegevens | geen gegevens |
1.7yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: CATX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 1.8yrs | US$1.46m | 0.031% $ 250.9k | |
Independent Director | 1.8yrs | US$320.06k | 0.063% $ 516.8k | |
Independent Director | 1.8yrs | US$320.06k | geen gegevens | |
Independent Director | 1.4yrs | US$390.70k | geen gegevens | |
Chairperson of the Board | 6.4yrs | US$671.73k | 0.24% $ 2.0m |
1.8yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: CATX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.